FDA approved fluorine-containing drugs in 2023

Qian Wang ¹Yeping Bian ²Gagan Dhawan ³Wei Zhang ⁴Alexander E.Sorochinsky ⁵Ata Makarem ⁶Vadim A.Soloshonok ⁷Jianlin Han¹

扫码查看

作者信息

1. Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources,College of Chemical Engineering,Nanjing Forestry University,Nanjing 210037,China
2. Jiangsu Province Geriatric Hospital,Nanjing 210024,China
3. School of Allied Medical Sciences,Delhi Skill and Entrepreneurship University,and Department of Biomedical Science,Acharya Narendra Dev College,University of Delhi,New Delhi 110019,India
4. Department of Chemistry,University of Massachusetts Boston,Boston,MA 02125,United States
5. V.P.Kukhar Institute of Bioorganic Chemistry and Petrochemistry,The National Academy of Sciences of Ukraine,Kyiv 02094,Ukraine
6. Department of Chemistry,University of Hamburg,Martin-Luther-King-Platz 6,Hamburg 20146,Germany
7. Department of Organic Chemistry Ⅰ,Faculty of Chemistry,University of the Basque Country UPV/EHU,Paseo Manuel Lardizábal 3,San Sebastián 20018,Spain;IKERBASQUE,Basque Foundation for Science,María Díaz de Haro 3,Plaza Bizkaia,Bilbao 48013,Spain
折叠

Abstract

This review profiles twelve fluorine-containing drugs approved by the US Food and Drug Administration(FDA)for the clinic in 2023.These small molecule drugs represent such therapeutic areas as cancer,neu-romuscular disorder,immunodeficiency,virology,and infectious diseases.Medicinal chemistry discovery,biological activity,and synthetic routes have been discussed for each drug.Also,new trends in structural positioning,functionality,and degree of fluorination are discussed.Besides fluorination,the importance of amino acid residues and chirality in the design of new pharmaceuticals is highlighted.

Key words

Fluorine-containing compounds/Blockbuster drugs/Pharmaceuticals/Anti-cancer/Drug design and development/Asymmetric synthesis

引用本文复制引用

出版年

2024

中国化学快报(英文版)

中国化学会

中国化学快报(英文版)

CSTPCDCSCD

影响因子：0.771

ISSN：1001-8417

段落导航